Technology Bundle ID

Iodonium Analogs as Inhibitors of NADPH Oxidases and other Flavin Dehydrogenases and their Use for Treating Cancer

Lead Inventors
James Doroshow (NCI)
Charles Kane ()
Jiamo Lu ()
Krishnendu Roy ()
Md Tafazzal Hossain ()
Prabhakar Risbood ()
Development Status
Pre-clinical (in vivo)

Diverse human cancers like colorectal, pancreatic, ovarian, melanoma, and pre-cancers express NADPH oxidases (NOX) at high levels. Reactive oxygen species (ROS) produced from metabolic reactions catalyzed by NOX in tumors are essential to the tumor’s growth. Though drugs that inhibit ROS production by NOX could be effective against a variety of human cancers, these types of drugs are not widely available.

Investigators at the Developmental Therapeutics Branch of the National Cancer Institute (NCI) have synthesized novel analogs of diphenylene iodonium (DPI) and di-thienyl-iodonium (DTI) as inhibitors of NOX and other flavin dehydrogenases for the treatment and prevention of cancer and inflammation-related conditions. Several of these inhibitors displayed potency in vitro that were superior to their parent molecules and were effective against diverse cancer cell lines representing acute lymphocytic leukemia, chronic myelogenous leukemia, myeloma, large cell immunoblastic lymphoma, non-small cell lung cancer, colon, melanoma, and renal cancer. In vivo validation of DPI and DTI using human colon cancer xenografted mice yielded a statistically significant reduction in the average rate of tumor growth in mice administered either DPI or DTI compared to control mice.

Investigators at the NCI have synthesized a novel class of drugs capable of slowing ROS-mediated tumor growth by targeting NOX. The NCI seeks research co-development partners and/or licensees for further development of these novel iodonium analogs.

Commercial Applications
  • Therapy to control chronic inflammatory conditions – including precancerous lesions
  • Targeted therapy for treating cancerous tumors expressing NOX
  • Diabetes
  • Neuropathies 
Competitive Advantages
  • Inactivate key kinases involved in tumor cell survival pathways
  • Optimized PDI specificity and selectivity lessens risk of off-target effects
  • Could become the first marketed drug, that depends on ROS to proliferate, to treat various cancers

Request More Info

Licensing Contact: